Render Target: STATIC
Render Timestamp: 2024-12-09T10:58:16.660Z
Commit: 224419269841c11382c4555dbee545259bf6c379
XML generation date: 2024-09-30 01:59:42.184
Product last modified at: 2024-09-30T08:01:52.782Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CEMIP (E8Y4R) Rabbit mAb #32041

Filter:
  • IF

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 170
    Source/Isotype Rabbit IgG
    Application Key:
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Immunofluorescence (Immunocytochemistry) 1:200 - 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CEMIP (E8Y4R) Rabbit mAb recognizes endogenous levels of total CEMIP protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human CEMIP protein.

    Background

    CEMIP (KIAA1199, HYBID) was originally described in patients affected by nonsyndromic hearing loss due to point mutations (1). One important role of the protein is the catabolic metabolism of hyaluronan by binding and depolymerizing the high molecular weight hyaluronan to low molecular weight hyaluronan, which contributes to cancer progression and inflammatory disease development (2,3). CEMIP further facilitates cancer progression by promoting WNT/β-catenin, EGFR, and calcium signaling pathways through direct interaction with pathway components (4-7). Aberrant high expression of CEMIP is associated with various types of cancer, where it plays key roles in tumor initiation, progression, metastasis, and epithelial-mesenchymal transition (EMT) (8). High levels of secreted CEMIP are found in inflammatory arthritis, osteoarthritis, atherosclerosis, and inflammatory bowel disease (9,10). Gene knockdown of CEMIP reduces progression of these diseases. CEMIP is a potential target for cancer and inflammatory arthritis management (11,12).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.